Frontiers in Psychiatry
July 22, 2022
M. Cigognini, A. G. Guirado, Denise van de Meene et al.
Objective Ketamine, an N-methyl D-aspartate (NMDA) receptor antagonist, can promote rapid action in the management of individuals with treatment-resistant depression (TRD) at sub-anesthetic doses. However, few studies have investigated the long-term use of ketamine administered intravenously (IV) and intranasally (IN). We report the design and rationale of a therapeutic trial for assessing the...
Frontiers in Psychiatry
July 22, 2022
Lai Fong Chan, Luke Sy-Cherng Woon, Nuur Asyikin Mohd Shukor et al.
2 citations
A significant proportion of patients with treatment-resistant depression do not attain functional recovery despite administration of multiple steps of pharmacotherapeutic strategies. This highlights the elusiveness of meeting unmet needs in existing pharmacotherapies for treatment-resistant depression. There is accumulating evidence that antidepressant agents involving the glutamatergic system...
Frontiers in Psychiatry
July 8, 2022
Maud Rothärmel, Cherifa Benosman, Wissam El-Hage et al.
31 citations
Introduction: Major depressive disorder (MDD) is more likely to resist to usual treatment when it is associated with post-traumatic stress disorder (PTSD). Capitalizing on the effect of ketamine in both treatment-resistant depression (TRD) and PTSD, we conducted a study in order to assess the efficacy of intranasal (IN) Esketamine in patients having TRD with comorbid PTSD. Materials and...
The World Journal of Biological Psychiatry
July 4, 2022
Monika Dmitrzak-Weglarz, M. Tyszkiewicz-Nwafor, Filip Rybakowski et al.
Abstract Objectives This study attempts to assess the concentration of two opposite-acting adipokines (anti-inflammatory adiponectin and pro-inflammatory resistin) in antidepressant-resistant patients undergoing ketamine infusion (KI) and electroconvulsive therapy (ECT). Methods The study group comprised 52 patients hospitalised due to episodes of depression in the course of bipolar disorders....
Psychiatry Research
July 1, 2022
Mu-Hong Chen, Chih-Ming Cheng, Cheng-Ta Li et al.
BACKGROUND This posthoc analysis compared the antidepressant and antisuicidal effects of low-dose ketamine infusion with those of repetitive transcranial magnetic stimulation (rTMS) on treatment-resistant depression (TRD). METHODS In the ketamine infusion trial, 48 patients with TRD were randomized to receive a single infusion of 0.5 mg/kg ketamine or normal saline. In the rTMS trial, 105...
Psychopharmacology
July 2022
Hildegard A Wulf, Caroline A Browne, Carlos A. Zarate et al.
Emerging evidence has implicated the endogenous opioid system in mediating ketamine's antidepressant activity in subjects with major depressive disorder. To date, mu opioid receptors have been suggested as the primary opioid receptor of interest. However, this hypothesis relies primarily on observations that the opioid antagonist naltrexone blocked the effects of ketamine in humans and rodents....
Behavioural Brain Research
July 1, 2022
Li-Min Zhang, Na Liu, Lucy Cao et al.
BACKGROUND Anesthesia and psychotropic drugs in pregnant women may cause long-term effects on the brain development of unborn babies. The authors set out to investigate the neurotoxicity of S-ketamine, which possesses anesthetic and antidepressant effects and may cause attention deficit hyperactivity disorder (ADHD)- and depression-like behaviors in offspring mice. METHODS Pregnant mice were...
Iranian Journal of Psychiatry
July 1, 2022
Ahmad Shamabadi, Ali Ahmadzade, Ali Aqamolaei et al.
Objective: Available treatments of depression have limited efficacy and unsatisfactory remission rates. This study aims to review randomized controlled trials (RCTs) investigating effects of glutamate receptor modulators in treating patients with resistant depression. Method : The study protocol was registered in PROSPERO (CRD42021225516). Scopus, ISI Web of Science, Embase, Cochrane Library,...
Journal of Affective Disorders
July 1, 2022
Thomas D Hull, Matteo Malgaroli, Adam Gazzaley et al.
59 citations
BACKGROUND At-home Ketamine-assisted therapy (KAT) with psychosocial support and remote monitoring through telehealth platforms addresses access barriers, including the COVID-19 pandemic. Large-scale evaluation of this approach is needed for questions regarding safety and effectiveness for depression and anxiety. METHODS In this prospective study, a large outpatient sample received KAT over...
Frontiers in Pain Research
June 27, 2022
Dianna E. Willis, Peter A. Goldstein
6 citations
The phencyclidine-derivative ketamine [2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one] was added to the World Health Organization's Model List of Essential Medicines in 1985 and is also on the Model List of Essential Medicines for Children due to its efficacy and safety as an intravenous anesthetic. In sub-anesthetic doses, ketamine is an effective analgesic for the treatment of acute pain...